Upcoming webinars

Register now for our upcoming webinars!

More info coming soon!

Stay tuned for more webinars here!

More info coming soon!

Stay tuned for more webinars here!

More info coming soon!

Stay tuned for more webinars here!

On demand

Webinar 2023-01-16


Breast Oncology Highlights 


Agenda

7.00 – 7.05 Welcome and introduction, Renske Altena, Jonas Bergh
7.05 – 7.30 Highlights from triple negative breast cancer with a focus on immunotherapy 2022, Marleen Kok
7.30 – 7.35 Q&A, discussion
7.35 – 8.00 Highlights from luminal tumors and fertility issues 2022, Matteo Lambertini
8.00 – 8.05 Q&A, discussion
8.05 – 8.30 Highlights from HER2-positive and HER2-low breast cancer 2022, Javier Cortes
8.30 – 8.35 Q&A, discussion
8.35 – 8.45 Discussion and closing remarks by moderators Renske Altena, Jonas Bergh


Webinar 2022-06-20


ASCO Highlight Breast Cancer


Agenda

7.00-7.05 Welcome, Renske Altena
7.05-7.25 Triple negative breast cancer and immunotherapy for breast cancer, Marleen Kok
7.25-7.35 Q&A
7.35-7.55 HER2-positive breast cancer, Javier Cortes
7.55-8.05 Q&A
8.05-8.25 Luminal tumors and fertility issues, Matteo Lambertini
8.25-8.35 Q&A
8.35-8.40 Concluding remarks Jonas Bergh


Webinar 2022-05-02

First line systemic therapy in metastatic renal cell carcinoma

Agenda

16:00 – 16:05 Welcome

16:05 – 16:35 Lecture with Dr. Neeraj Agarwal

16:35 – 16:50 Questions and discussion with invited panel:Dr. Sven Lundstam, Associate Professor, Chief Physician Urology, Sahlgrenska University Hospital, Gothenburg and Dr. Fabian Hofmann, Supervising Senior Assossiate, Renal Cell Carcinoma Guidlines panel European Association of Urology, Sunderby Sjukhus




More content comming soon!

Welcome to Oncology Congress News
These pages are aimed at people who work in health care. Do you work in healthcare?
Why do we ask this? This page may contain advertisements for prescription drugs. According to the Pharmaceuticals Act, marketing of prescription drugs may not be directed at the general public, we must therefore ask this question.